For media inquiries: Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219
May 3, 2024
Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024
March 14, 2024
Mozart Therapeutics Presents Non-clinical Data on Lead Program, MTX-101 for Treatment of Autoimmune Diseases, at Society of Toxicology Annual Meeting 2024
November 13, 2023
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023
More Press Releases